The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 18, 2005
Filed:
Nov. 05, 1999
Sean V. Tavtigian, Salt Lake City, UT (US);
David H.-f. Teng, Salt Lake City, UT (US);
Jacques Simard, St. Augustin de DesMaures, CA;
Johanna M. Rommens, Toronto, CA;
Lisa A. Cannon Albright, Salt Lake City, UT (US);
Susan L. Neuhausen, Salt Lake City, UT (US);
Sean V. Tavtigian, Salt Lake City, UT (US);
David H.-F. Teng, Salt Lake City, UT (US);
Jacques Simard, St. Augustin de DesMaures, CA;
Johanna M. Rommens, Toronto, CA;
Lisa A. Cannon Albright, Salt Lake City, UT (US);
Susan L. Neuhausen, Salt Lake City, UT (US);
Myriad Genetics, Inc., Salt Lake City, UT (US);
University of Utah Research Foundation, Salt Lake City, UT (US);
Hospital for Sick Children, Toronto, CA;
Abstract
The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the HPC2 gene, (including gene therapy, protein replacement therapy, protein mimetics, and inhibitors). The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the HPC2 gene for mutations, which are useful for diagnosing the predisposition to prostate cancer.